Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Current Drug Metabolism
Title:Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Volume: 15 Issue: 2
Author(s): Vojtech Huser, Samuel G. Johnson, Marc S. Williams, Mary V. Relling, Dan Roden, C. Michael Stein, Rachel F. Tyndale, Jesse J. Swen, Mia Wadelius, Stuart A. Scott, Kristine R. Crews, Otito F. Iwuchukwu, Ming Ta Michael Lee, Kelly E. Caudle, Robert R. Freimuth, Jose A.G. Agundez, Matthias Schwab, Caroline F. Thorn, Katrin Sangkuhl, Ellen M. McDonagh, Li Gong, Michelle Whirl-Carrillo, Daniel J. Muller, James M. Hoffman and Teri E. Klein
Affiliation:
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Export Options
About this article
Cite this article as:
Huser Vojtech, Johnson G. Samuel, Williams S. Marc, Relling V. Mary, Roden Dan, Stein Michael C., Tyndale F. Rachel, Swen J. Jesse, Wadelius Mia, Scott A. Stuart, Crews R. Kristine, Iwuchukwu F. Otito, Michael Lee Ta Ming, Caudle E. Kelly, Freimuth R. Robert, Agundez A.G. Jose, Schwab Matthias, Thorn F. Caroline, Sangkuhl Katrin, McDonagh M. Ellen, Gong Li, Whirl-Carrillo Michelle, Muller J. Daniel, Hoffman M. James and Klein E. Teri, Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 2014; 15 (2) . https://dx.doi.org/10.2174/1389200215666140130124910
DOI https://dx.doi.org/10.2174/1389200215666140130124910 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG
Current Alzheimer Research Theoretical Approaches to Protein Aggregation
Protein & Peptide Letters Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Closing the Gap Between Cognitive Performance and Real-World Functional Outcome in Schizophrenia: The Importance of Metacognition
Current Psychiatry Reviews Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Gender Disparity in Pediatric Diseases
Current Molecular Medicine A Subsystem of Communication in Digital PET based on Ethernet and CAN
Neuroscience and Biomedical Engineering (Discontinued) Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses
Current Clinical Pharmacology Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Molecular and Pharmaceutical Aspects of Novel Methods and Materials for the Prevention of Tooth Structure Loss
Current Pharmaceutical Biotechnology Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member:
Cardiovascular & Hematological Agents in Medicinal Chemistry Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Drusen in the Peripheral Retina of the Alzheimer’s Eye
Current Alzheimer Research Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine